Terkko Navigator / Oncoscience

Dysregulated PJA1-TGF-β signaling in cancer stem cell-associated liver cancers

Uncovering the deubiquitinase activity landscape of breast cancer

Getting quantitative on the effects of somatic mutation on cancer

Pharmacogenomics based precision medicine in gastroesophageal cancers: way to move forward?

Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction

Does the natural product, honokiol, have value in the battle against osimertinib resistance?

Eradication of CSCs: the roadmap for curing cancer

Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer

Fragile site instability: measuring more than breaks

Genomic landscape of inflammatory breast cancer identifies potential actionable genetic alterations

RNA Binding Protein LIN28B: a prime time player shaping neuroblastoma aggression and metastasis

A highway to carcinogenesis: the role of IQGAP1, a signaling scaffolding protein, in head and neck cancer development

The advent of precision epigenetics for medulloblastoma

Future directions of neoadjuvant therapy in pancreatic cancer

Improving therapy in metastatic uveal melanoma by understanding prior failures

Checkpoint blockade therapy for functioning pituitary adenomas

Identifying new targets for rectal cancer treatment

4-1BB Agonism as a strategy to license immune checkpoint blockade in glioblastoma

HUNK Signaling in Metastatic Breast Cancer

Deciphering high risk molecular alterations in gastrointestinal malignancy utilizing an extreme outlier strategy

Heavenly HELLS? A potential new therapeutic target for retinoblastoma

Computational disease progression modeling can provide insights into cancer evolution

Repeated stereotactic radiosurgery for the treatment of relapsed brain metastases: is it time to give up whole-brain radiotherapy?

Cancer research - can the entity be bigger than the sum of its parts?

Metabolic Reprogramming by c-MET Inhibition as a Targetable Vulnerability in Glioblastoma

Cracking the riddle of dedifferentiated liposarcoma: is EV-MDM2 a key?

Overexpression of microRNA-145 inhibits tumorigenesis through autophagy in chemotherapy and radiation resistant neuroblastoma cells

SOCS1: phosphorylation, dimerization and tumor suppression

Improving patient classification and biomarker assessment using Gaussian Mixture Models and Bayes' rule

Precision health for breast cancer metastasis: biomaterial scaffolds as an engineered metastatic niche to define, study, and monitor metastatic progression

Tissue-agnostic cancer drugs in the fight against molecular subsets of metastases of unknown origin

Inside a mystery of oncoscience: The cancer-sniffing pets

Cytochrome P450 monooxygenase/soluble epoxide hydrolase-mediated eicosanoid pathway in colorectal cancer and obesity-associated colorectal cancer

Menin: Expanding and dichotomous roles in cancer

Correction: Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment

In situ analysis of Her2 DNA and RNA in retinoblastoma and adjacent retina

Senescence regulation by nuclear N-WASP: a role in cancer?

Pomalidomide-induced changes in the pancreatic tumor microenvironment and potential for therapy

H2Bub1: Guardian of chromatin accessibility in ovarian cancer

Suppression of vascular endothelial growth factor expression in breast cancer cells by microRNA-125b-mediated attenuation of serum amyloid A activating factor-1 level

Genome atlas analysis based profiling of Akt pathway genes in the early and advanced human prostate cancer

CDK12 inactivation across solid tumors: an actionable genetic subtype

ZC3H12A Expression in Different Stages of Colorectal Cancer

Localized RAS signaling drives cancer

Liquid Biopsies Using Plasma Exosomal Nucleic Acids

Direct Inhibition ofβ-catenin: A new strategy for colorectal cancer

DNA methylation in senescence, aging and cancer

Targeting primary cilia - associated signaling in glioblastoma: guided approach for drug development

Translating the role of PARP inhibitors in triple-negative breast cancer

Still a hopeless case for personalized oncology? Pancreatic cancer revisited